Influenza viral infections represent a serious public health problem, with influenza virus causing a contagious respiratory disease which is most effectively prevented through vaccination. Segments 7 (M) and 8 (NS) of the influenza virus genome encode mRNA transcripts that are alternatively spliced to express two different viral proteins. This study describes the generation, using reverse genetics, of three different recombinant influenza A/Puerto Rico/8/1934 (PR8) H1N1 viruses containing M or NS viral segments individually or modified M or NS viral segments combined in which the overlapping open reading frames of matrix 1 (M1)/M2 for the modified M segment and the open reading frames of nonstructural protein 1 (NS1)/nuclear export protein (NEP) for the modified NS segment were split by using the porcine teschovirus 1 (PTV-1) 2A autoproteolytic cleavage site. Viruses with an M split segment were impaired in replication at nonpermissive high temperatures, whereas high viral titers could be obtained at permissive low temperatures (33°C). Furthermore, viruses containing the M split segment were highly attenuated in vivo, while they retained their immunogenicity and provided protection against a lethal challenge with wild-type PR8. These results indicate that influenza viruses can be effectively attenuated by the rearrangement of spliced segments and that such attenuated viruses represent an excellent option as safe, immunogenic, and protective live-attenuated vaccines. Moreover, this is the first time in which an influenza virus containing a restructured M segment has been described. Reorganization of the M segment to encode M1 and M2 from two separate, nonoverlapping, independent open reading frames represents a useful tool to independently study mutations in the M1 and M2 viral proteins without affecting the other viral M product.
Influenza viruses are enveloped pathogens that belong to the Orthomyxoviridae family and contain a segmented genome of eight single-stranded RNA molecules with negative polarity (1). Influenza virus infections cause both seasonal epidemics and occasional pandemics when novel viruses are introduced into humans (2). Despite comprehensive vaccination programs, the World Health Organization (WHO) estimates that the global disease burden from influenza results in 1 billion infections, 3 million to 5 million cases of severe disease, and between 300,000 and 500,000 deaths annually (3). Therefore, infection with influenza virus poses a threat to human health and results in significant negative economic impacts on society every year (4). The public health concerns posed by influenza viruses are aggravated by their efficient transmission and the limited antiviral therapeutic options (5). Hence, vaccination remains our best medical intervention to protect humans against influenza virus (6), even though the effectiveness of current vaccines is suboptimal (7). To date, the U.S. Food and Drug Administration (FDA) approves three types of influenza virus vaccines for human use: inactivated vir...